Kk. Goncz et al., Expression of Delta F508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR, GENE THER, 8(12), 2001, pp. 961-965
The development of gene targeting strategies for specific modification of g
enomic DNA in human somatic cells has provided a potential gene therapy for
the treatment of inherited diseases. One approach, small fragment homologo
us replacement (SFHR), directly targets and modifies specific genomic seque
nces with small fragments of exogenous DNA (400-800 bp) that are homologous
to genomic sequences except for the desired modification. This approach ha
s been effective for the in vitro modification of exon la in the cystic fib
rosis transmembrane conductance regulator (CFTR) gene in human airway epith
elial cells. As another step in the development of SFHR for gene therapy st
udies were carried out to target and modify specific genomic sequences in e
xon 10 of the mouse CFTR (mCFTR) in vivo. Small DNA fragments (783 bp), hom
ologous to mCFTR except for a 3-bp deletion (Delta F508) and a silent mutat
ion which introduces a unique restriction site (Kpnl), were instilled into
the lungs of normal mice using four different DNA vehicles (AVE, LipofectAM
INE, DDAB, SuperFect). Successful modification was determined by PCR amplif
ication of DNA or mRNA-derived cDNA followed by Kpnl digestion. The results
of these studies showed that SFHR can be used as a gene therapy to introdu
ce specific modifications into the cells of clinically affected organs and
that the cells will express the new sequence.